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Abstract
Background: HLA-C is an important ligand for killer immunoglobulin like receptors (KIR) that regulate natural killer (NK) cell
function. Based on KIR specificity HLA-C molecules are allocated into two groups, HLA-C1 or HLA-C2; HLA-C2 is more
inhibiting to NK cell function than HLA-C1. We studied the clinical importance of HLA-C genotypes on the long-term graft
survival of 760 kidney transplants performed at our centre utilising a population based genetic study and cell culture model
to define putative mechanisms.
Methods and Findings: Genotyping was performed using conventional DNA PCR techniques and correlations made to
clinical outcomes. We found that transplant recipients with HLA-C2 had significantly better long-term graft survival than
transplant recipients with HLA-C1 (66% versus 44% at 10 years, log-rank p=0.002, HR=1.51, 95%CI=1.16–1.97). In in-vitro
NK and dendritic cell (DC) co-culture model we made several key observations that correlated with the population based
genetic study. We observed that donor derived NK cells, on activation with IL-15, promoted differential HLA-C genotype
dependent DC maturation. In NK-DC co-culture, the possession of HLA-C2 by DC was associated with anti-inflammatory
cytokine production (IL-1RA/IL-6), diminished DC maturation (CD86, HLA-DR), and absent CCR7 expression. Conversely,
possession of HLA-C1 by DC was associated with pro-inflammatory cytokine synthesis (TNF-a, IL-12p40/p70), enhanced DC
maturation and up-regulation of CCR7 expression. By immunohistochemistry the presence of donor NK cells was confirmed
in pre-transplant kidneys.
Conclusions: We propose that after kidney transplantation IL-15 activated donor derived NK cells interact with recipient DC
with less activation of indirect allo-reactivity in HLA-C2 positive recipients than HLA-C1 positive recipients; this has
implications for long-term graft survival. Early events following kidney transplantation involving NK-DC interaction via KIR
and HLA-C immune synapse may have a central role in long-term kidney transplant outcomes.
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Introduction
Kidney transplantation is the standard of care for many people
with end stage kidney disease [1]. However, whilst acute rejection
rates and early graft loss have improved substantially over the past
four decades, progressive chronic allograft injury (CAI) remains a
very common cause of late graft loss [2,3]. A major component of
CAI is orchestrated by the adaptive components of the immune
system including dendritic cells (DC), T cells and B cells [4–8].
Our knowledge of the link between innate and adaptive immunity
in CAI including the contribution of NK cells is incomplete. This
is an important shortfall, as NK cells have a central role in
modulating the development of the adaptive response through
interactions with HLA-C molecules on target cells [9,10]. HLA-C
molecules act as ligands for NK cell expressed inhibitory killer
immunoglobulin-like receptors (KIR), with subsequent modulation
of NK cell function. HLA-C molecules are allocated into two
groups based on their KIR specificity: (i) HLA-C group 1 (C1)
specific for KIR receptor 2DL2/3; (ii) HLA-C group 2 (C2)
specific for KIR receptor 2DL1 [10]. Differential KIR and HLA
expression appear to influence clinical outcomes in various
diseases including cervical neoplasia [11], pre-eclampsia [12],
antiviral immune response [13], hepatitis C [14] and liver
transplantation [15]. As the co-expression of KIR 2DL1 and
2DL3 on NK cells occurs in greater than 90% of the population,
the major determinant of NK cell inhibition is the differential
expression of HLA-C ligands. Functional studies performed by
Ahlenstiel and colleagues (2008) investigating antiviral responses
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23631in-vitro showed diminished degranulation and cytokine produc-
tion by NK cells in HLA-C2 compared with HLA-C1 targets.
They proposed that NK cell inhibition through interactions
between KIR2DL3 and HLA-C1 is weaker than inhibition
conferred through KIR2DL1/HLA-C2 interactions [13].
In liver transplantation, we found that HLA-C2 expression by
the allograft was protective against the development of chronic
rejection, graft cirrhosis and late graft loss [15]. There is limited
data on the effect of KIR and KIR ligands on clinical outcomes
following kidney transplantation. In a study of 224 kidney
transplant recipients, Kunert and colleagues (2007) showed that
expression of a HLA-C2 homozygous genotype by the allograft
was associated with a reduced incidence of acute rejection [16].
Nowak and colleagues (2010) genotyped 285 recipients of kidney
transplants and demonstrated that the presence of HLA-C2 and
absence of KIR2DS5 in the recipient correlated with increased
episodes of acute allograft rejection. Conversely they found that
the presence of both HLA-C1 and KIR2DS5 in the recipient was
protective against acute allograft rejection [17]. In a study
comprising of 2,757 kidney transplants, Tran and colleagues
(2005) investigated the impact of KIR ligand matching on graft
survival. Whilst they showed no correlation between KIR ligand
matching and graft survival they did not specifically investigate the
relationship between differential HLA-C expression and graft
outcomes [18].
The predominant subgroup of NK cells (.95% of peripheral
blood NK cells) are CD56
dimCD16
+ and possess KIR receptors
(95%) [19,20]. In addition to their role in the elimination of
tumour and virus transformed cells, they also interact with DC.
This interaction is contact dependent and bidirectional, involving
multiple cytokine synthesis including IFN-c, TNF-a, IL-12, IL-15,
IL-18 and HMGB1 [21–25]. During NK-DC co-culture, NKp30
engagement triggers intracellular mechanisms that are further
modulated by KIR and HLA-C interactions [26,27]. Dendritic
cells that are matured during NK-DC crosstalk are potent T-cell
primers [28] and promote Th1 polarisation [29].
Following kidney transplantation, the allograft undergoes
significant ischaemia reperfusion injury (IRI) with release of pro-
inflammatory cytokines [30] including IL-15 [31–33] and
recruitment of recipient monocytes and DCs [34]. Passenger
leukocytes transferred in the allograft from donor to recipient
augment the allo-immune response. Allogeneic donor derived NK
cells transferred by this process may be a predominant activator of
recipient DCs. Furthermore DC maturation supersedes cytolysis
during IRI as products of cellular damage trigger TLR4 expressed
on DC [30]. Even in the presence of conventional immunother-
apy, IL-15 will promote NK-DC crosstalk, leading to accelerated
maturation of DC with allo-antigen presenting capacity.
In this study, we investigated the influence of HLA-C genotype
on graft survival. We found that recipients with HLA-C2 had
significantly better long-term graft survival after kidney transplan-
tation than those without HLA-C2 (i.e. HLA-C1 homozygotes).
Based on these observations we hypothesised that the interaction
between allogeneic donor derived NK cells transferred in the
allograft at time of transplantation and recipient DC are
differentially modulated by the engagement of donor KIR and
recipient HLA-C on DC. This hypothesis was based on the
premise that as HLA-C2 is more inhibiting to NK cell function
than HLA-C1, DC expressing HLA-C2 should undergo less
maturation than those expressing HLA-C1, with a subsequent
impact on T-cell priming. This was investigated by an NK-DC co-
culture model controlled for confounding factors by utilising: (i)
NK cells from donors heterozygous for HLA-C (C1/C2), negative
for HLA-Bw4, haplotype AA with one activating KIR2DS4 and
with 3 inhibitory KIR2DL1, 2DL3, and 3DL1; (ii) DC from donors
negative for HLA-Bw4 and either homozygous for HLA-C1 or
HLA-C2. This process of selection excluded the potential
confounding effects of HLA-Bw4 through interactions with
3DL1 and allowed direct comparisons to be made between
HLA-C1 homozygous and HLA-C2 homozygous DCs. Under
these conditions, allogeneic NK-DC co-cultures facilitated an
assessment of the mechanisms of the association of HLA-C
genotype with graft survival.
Materials and Methods
Ethics Statement
Approvals for all parts of this study were granted by the South
Birmingham Research Ethics Committee. Informed consent was
not required as data were analyzed anonymously. The ethics
committee specifically waived the need for consent.
Population Genetics
Nine hundred and fifty adult kidney transplant recipients were
treated at the Queen Elizabeth Hospital, Birmingham between
1996 and 2004. DNA was available for a total of 890 kidney
donors and 760 transplant recipients. The final study population
therefore comprised 760 renal transplant pairs all with complete
long-term follow-up; 640 were deceased donor transplants and 120
were live donor transplants; 652 recipients were first time kidney
transplants, 86 were second and 22 were third transplant.
By polymerase chain reaction sequence specific primer (PCR-
SSP) technique, donor and recipient DNA were genotyped for the
presence of the three major KIR ligand groups, HLA-C1, HLA-
C2 and HLA-Bw4. These were assigned directly by using specific
oligonucleotide primers to type the codon corresponding to amino
acid 80 for HLA-C and codons 80–83 for HLA-Bw4. Similarly,
KIR genotyping was performed for inhibitory and activating KIR
using PCR-SSP with primers based on those published by
Uhrberg [35]; Four inhibitory KIRs (2DL1, 2DL2, 2DL3 and
3DL1) and seven activating KIRs (2DS1, 2DS2, 2DS3, 2DS4,
2DS4v, 2DS5, and 3DS1) were analysed. The clinical outcome
data comprised biopsy proven acute rejection, graft survival and
patient survival. Graft loss was defined as graft failure requiring
dialysis (n=163). Both death non-censored and death censored
graft survival were calculated. For death non-censored graft
survival, patient death with a functioning graft was also defined as
graft failure and therefore included as graft loss (n=219). Causes
of graft loss and patient death are listed in Table 1 and 2. Patient
death (n=56, Table 2) from all causes was included in the analysis
of patient survival. Preliminary power calculations were performed
for this study and based on the assumption that 10-year graft
survival for kidney transplants at our centre is 65%, then for 760
cases (assuming 40% are HLA-C1 homozygous and the remaining
Table 1. Causes of graft loss following kidney
transplantation.
Cause of graft loss (n=163) Incidence
Chronic allograft injury 124 (76%)
Vascular thrombosis 24 (14.7%)
Acute rejection 7 (4.3%)
Recurrent of primary renal disease 6 (3.7%)
Infection of allograft 2 (1.3%)
doi:10.1371/journal.pone.0023631.t001
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allele therefore the heterozygous and HLA-C2 homozygous
genotype combined) this study size has a 90% power to detect a
hazard ratio of 1.49 for graft failure.
Immunohistochemistry
Pre-transplant kidney (n=5) biopsies were available and
assessed for the presence of donor derived NK cells. Biopsies
were taken prior to transplantation, and fixed in formalin. The
method used for the development of slides include dewaxing and
antigen retrieval obtained by W-cap system (Bio-Optica) and
staining with a mouse monoclonal anti-CD56 antibody (IgG2b
Novocastra) used at a dilution of 1:50 and visualised with the
EnVision detection system (DAKO). Negative controls were
performed using corresponding isotype antibody staining. Cell
counts (degree of infiltration) were performed using light
microscopy and counting 10 randomly selected high power fields
at a magnification of 4006(area=0.17 mm
2).
In-vitro NK-DC co-culture
In order to analyse the influence of DC HLA-C genotype on
NK-cell mediated maturation of DC, we developed a co-culture
model to exclude the known confounding factors detailed in the
introduction.
Whole blood samples were obtained from healthy laboratory
donors for the isolation of purified and enriched NK and DC cell
populations from PBMC using magnetic cell separation. The
development of an NK-DC co-culture system required two
independent steps. Firstly, DC were prepared using a pre-
optimised magnetic cell sorting kit (Miltenyi Biotec, Surrey, UK)
for the extraction of CD14
+ monocytes from PBMC. Following
isolation, CD14
+ monocytes were treated with 100 ng/ml of GM-
CSF (Peprotech, London, UK) and 1000 U/ml of IL-4 (Pepro-
tech, London, UK) in RPMI containing 5% autologous serum and
maintained in a 5% CO2 cell culture incubator at 37uC for 5 days.
This altered their phenotype to that of immature dendritic cells
(iDC) with a population of .90% CD14
2CD1a
+ iDC cells,
comparable with the published literature [21–23]. On day 5, NK
cells were isolated from PBMC using a pre-optimised magnetic cell
sorting kit (Miltenyi Biotec, Surrey, UK) for the extraction of
CD56
+CD16
+ NK cell. Purities of .98% were attained consistent
with published literature [21–23]. Allogeneic NK and iDC cells
were then co-cultured in the presence or absence of 1 ng/ml IL-15
(Peprotech, London, UK) in RPMI containing 10% foetal calf
serum (Sigma-Aldrich, Dorset, UK) for 48 hours in a 48 well plate
maintained in a 5% CO2 cell culture incubator at 37uC. Co-
culture cell ratios of 1:1 and 1:5 (NK:DC) were then studied as
these ratios are most favourable for DC maturation [21] and
should be consistent with the in-vivo relationship. Typically (at 1:1)
each well contained 0.25610
6 of each cell type in a final media
volume of 500 ml. The control wells had either DC or NK cells in
isolation. Trans-well experiments were performed using the same
conditions, but in the presence or absence of a 0.4 mm insert
(Costar, Fisher Scientific, UK) to separate NK cells and DC. At
the end of co-culture DC were tested for the expression of the
maturation markers CD86 (PE, 2331, BD Bioscience) and HLA-
DR (FITC, G46-6, BD Bioscience) and the chemokine receptor
CCR7 (PE, 150503, R&D Systems). The DC gate on flow
cytometry was defined by a combination of scatter plot and CD56
staining to identify NK cells. The D Mean Fluorescence Intensity
(D MFI) per experiment for CD86, HLA-DR and CCR7 was
calculated as the difference in MFI for DC in co-culture with NK
cells versus DC in isolation (background maturation). Correspond-
ing isotype controls (BD Bioscience) were used. Cells were
analysed using a FACSCalibur flow cytometer (Becton Dickinson)
with Winmdi 2.9 software (Scripps Research), acquiring informa-
tion from a total of 5,000 gated cells.
Co-culture supernatants were also collected and tested for the
presence of cytokines by multiplex assays [Cytokine 25-plex AB
Bead Kit, Human (BioSource
TM), from Invitrogen; data analysed
using LuminexH100
TM Analyser].
Comparison of means for DMFI and supernatant cytokine
synthesis was performed to compare responses for DC with HLA-
C1 genotype (n=4) versus DC with HLA-C2 genotype (n=4).
The NK and DC used in each experiment came from different lab
donors thus making these allogeneic interactions.
Statistical analysis
Actuarial data were analysed using the Kaplan-Meier method
and the log-rank test. Cox regression models for multivariable
analysis were used to identify independent factors contributing to
long-term graft loss. Mann-Whitney U test (Exact 2-tailed
significance) was used for comparing means of DMFI and
supernatant cytokines synthesis. All other correlations for variables
and comparison of means were performed using Kendall’s tau-b
and ANOVA tests respectively. Probability (p) values of less than
0.05 were considered significant for our analysis. All statistics were
performed using SPSS 14.0.
Results
HLA-C2 positive kidney transplant recipients have
significantly better long-term graft survival
Kaplan Meier survival analysis was performed for individual
KIR, KIR haplotypes and HLA-C/Bw genotypes for both donor
and recipient. Recipient HLA-C genotype was the only factor
found to influence survival outcomes and therefore tested further.
Frequency of genotypes was consistent with previous published
reports. Donor frequency for individual genes: 2DL1 98%, 2DL2
46%, 2DL3 92%, 3DL1 94%, 2DS1 40%, 2DS2 48%, 2DS3 30%,
2DS4 96%, 2DS5 31%, 3DS1 37%, HLA-C1 87%, HLA-C2 62%,
HLA-Bw4 35% and Haplotype AA 32%. Recipient frequency for
individual genes: 2DL1 95%, 2DL2 36%, 2DL3 97%, 3DL1 89%,
2DS1 28%, 2DS2 44%, 2DS3 28%, 2DS4 83%, 2DS5 33%, 3DS1
34%, HLA-C1 87%, HLA-C2 57%, HLA-Bw4 38% and
Haplotype AA 31%.
In contrast to liver transplantation, donor HLA-C genotype did
not have impact on survival outcomes in kidney transplantation.
However, recipient HLA-C genotype did have a major impact on
outcomes 10-year death non-censored graft survival was signifi-
cantly better for recipients with HLA-C2 compared with recipients
without HLA-C2 (65.7%. versus 43.8%, p=0.002; hazard ratio:
Table 2. Causes of patient death following kidney
transplantation.
Cause of patient death (n=56) Incidence
Cardiovascular disease 20 (35.7%)
Post-transplant lymphoproliferative disease 10 (17.9%)
Septicaemia 8 (14.3%)
Respiratory failure 6 (10.7%)
Cerebrovascular event 6 (10.7%)
Other malignant disease 6 (10.7%)
doi:10.1371/journal.pone.0023631.t002
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survival was also significantly better for recipients with HLA-C2
compared with recipients without HLA-C2 (74.2% versus 54.3%,
p=0.05;hazard ratio:1.36,95%CI:1.02–1.85)(figure 2).Ten-year
patient survival was significantly better for recipients with HLA-C2
compared with recipients without HLA-C2 (88.5% versus 80.4%,
p=0.004; hazard ratio: 2.12, 95% CI: 1.26–3.58) (figure 3). HLA-
C2 homozygous and heterozygous genotypes had comparable
survival outcomes, and both groups were superior to HLA-C1
homozygotes (HLA-C2/C2 versus HLA-C1/C2; ten-year death
non-censored graft survival 69.1% versus 64.1%, log-rank p=0.66;
ten-year death censored survival 80.5% versus 72.5%, log-rank
p=0.09; ten-year patient survival 88% versus 87%, log-rank
p=0.78). Re-transplants were not excluded from this analysis
because analysing re-transplants only demonstrated similar survival
benefit seen for recipients with HLA-C2 alleles. For re-transplants
10-year death non-censored graft survival was significantly better
for recipients with HLA-C2 compared with recipients without
HLA-C2 (60% versus 17.4%, p=0.02; hazard ration: 2.17, 95%
CI: 1.11–4.25). Ten-year death censored graft survival was also
significantly better for recipients with HLA-C2 compared with
recipients without HLA-C2 (72% versus 33%, p=0.05; hazard
ratio: 1.3, 95% CI: 1.23–1.7). Ten-year patient survival was
significantly better for recipients with HLA-C2 compared with
recipients without HLA-C2 (77% versus 52%, p=0.015; hazard
ratio: 3.7, 95% CI: 1.19–11.89) (figures not shown). This
observation further supports a recipient derived effect. Donor and
recipient HLA-Bw4, KIR haplotypes or KIR genotypes did not
influence clinical outcomes following kidney transplantation.
Furthermore KIR ligand matching did not influence clinical
outcomes consistent with previous observations [17].
Figure 1. Kaplan Meier survival curve showing death non-
censored graft survival for the presence or absence of HLA-C2
allele in the recipient. The presence of an HLA-C2 allele in the
recipient was associated with a significant improvement in death non-
censored graft survival (10-year survival: 65.7% versus 43.8%).
doi:10.1371/journal.pone.0023631.g001
Figure 2. Kaplan Meier survival curve showing death censored
graft survival for the presence or absence of HLA-C2 allele in
the recipient. The presence of an HLA-C2 allele in the recipient was
associated with a significant improvement in death censored graft
survival (10-year survival: 74.2% versus 54.3%).
doi:10.1371/journal.pone.0023631.g002
Figure 3. Kaplan Meier survival curve showing patient survival
for the presence or absence of HLA-C2 allele in the recipient.
The presence of an HLA-C2 allele in the recipient was associated with a
significant improvement in patient survival (10-year survival: 88.5%
versus 80.4%).
doi:10.1371/journal.pone.0023631.g003
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may influence clinical outcomes in kidney transplantation
(Table 3&4). This confirmed the association of the recipient
HLA-C2 allele with improved graft survival for both death non-
censored and death censored graft survival. Interestingly, in the
multivariable analysis, recipient HLA-C2 allele was not signif-
icantly associated with improved patient survival. Other than 4
HLA antigen mismatches we did not observe the relationship
between HLA mismatch and graft survival. Whilst HLA
mismatching is known to influence graft survival our study was
not designed to detect these as the number of cases per HLA
mismatch were small.
In table 5 the causes of graft loss were analysed in the context of
the absence or presence of HLA-C2. This analysis demonstrated
that chronic allograft injury and vascular thrombosis occurred
more frequently in the absence of HLA-C2 when compared to the
presence of HLA-C2.
HLA-C and KIR genotypes do not influence the incidence
of acute rejection
The correlation between the incidence of biopsy proven acute
rejection (33% in our kidney transplant population) and various
genotypes for donor and recipient was studied. Complete data was
available for 657 cases. The remaining 103 cases were excluded
because these patients were referred to other treatment centre for
their routine transplant follow-up and accurate data regarding acute
rejection episodeswere not available. The incidenceof acute rejection
did not correlate with individual KIR genotype, KIR haplotype, KIR
ligand genotype (HLA-C or Bw4), or KIR ligand matching.
Donor derived NK cells are present in the allograft at the
time of transplant
Immunohistochemical staining for CD56 confirms the presence
of NK cells in pre-transplant kidney tissue providing evidence that
at transplantation donor derived NK cells are present in the
Table 3. Demographics and distribution of parameters that are known to affect graft and patient survival after kidney
transplantation.
Demographics
Absence of HLA-C2
(n=303)
Presence of HLA-C2
(n=457) P value
Recipient age 43.0 (CI 41.2–44.8) 42.3 (CI 40.9–43.6) 0.49*
Donor age 43.5 (CI 41.6–45.4) 43.5 (CI 42.1–44.9) 0.96*
Recipient sex M:F 191:112 278:179 0.55
+
Donor sex M:F 180:123 236:221 0.03
+
Seropositive CMV in recipient 169 240 0.43
+
Seropositive CMV in donor 150 212 0.41
+
Type of transplant; Deceased donor: Live donor 258:45 382:75 0.60
+
Number of transplant
1 256 398 0.26
+
23 9 4 7
38 1 2
Acute Rejection 86 129 0.96
+
Type of CNI; Cyclosporin: Tacrolimus 290:15 434:21 0.90
+
Anti-CD25 monoclonal antibody 50 82 0.59
+
HLA mismatch (no. of antigens)
0 44 58 0.62
+
13 1 4 1
2 128 206
37 1 1 0 8
41 5 2 5
51 0 1 4
64 5
Mean mismatches per patient 2.09 2.15
DR locus mismatch (no. of antigens)
0 207 297 0.42
+
18 3 1 4 2
21 3 1 8
Mean mismatches per patient 0.36 0.41
As the analysis involved the comparison between absence of HLA-C2 in the recipient versus presence of HLA-C2 in the recipient groups were divided accordingly.
Absence of HLA-C2 represents HLA-C1 homozygous whereas presence of HLA-C2 combines both heterozygous and HLA-C2 homozygous groups. CI is 95% confidence
interval.
*indicates significance by ANOVA test,
+indicates significance by Kendall’s tau-b test.
doi:10.1371/journal.pone.0023631.t003
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performed using light microscopy and counting 10 randomly
selected high power fields at a magnification of 4006
(area=0.17 mm
2). Mean (6SEM) of 362 CD56 positive cells
were identified per high power field.
Optimal DC maturation in allogeneic NK-DC co-culture
requires cytokine IL-15 activation and is cell contact
dependent
Allogeneic interactions between NK and iDC without cytokine
activation led to minimal DC maturation. This was consistent with
previous observations [23,26]. In co-culture, the addition of 1 ng/
ml of IL-15 significantly augmented DC maturation with
increased expression of CD86, HLA-DR and CCR7. DC
maturation occurred optimally at NK-DC ratios of 1:1 consistent
with previous reports [21,22]. In trans-well experiments where IL-
15 activated NK and DC were separated by a porous membrane,
DC maturation did not occur, confirming that IL-15 activated NK
cell mediated DC maturation is contact dependent.
HLA-C2 expression by DC is associated with inhibited
maturation responses in NK-DC co-culture
The influence of HLA-C genotype on DC maturation in NK-
DC co-culture was assessed at cell ratios of 1:1 and 1:5 in the
presence of 1 ng/ml IL-15. In NK-DC co-culture at 1:1 cell ratios,
DC maturation (CD86 and HLA-DR) and chemokine expression
(CCR7) were significantly greater for HLA-C1 DCs (DMFI:
CD86=61.08615.40, HLA-DR=363.67673.21, CCR7=
52.35616.23) compared to HLA-C2 DCs (DMFI: CD86=
6.4366.12, HLA-DR=115.81640.00, CCR7=1.9161.91,)
(p,0.05, Mann-Whitney U test) (figure 5 & 6). Similarly at NK-
DC cell ratios of 1:5, CD86 and CCR7 expression were
significantly greater for HLA-C1 DCs (DMFI: CD86=
44.78610.39, CCR7=14.3568.77) than HLA-C2 DCs (DMFI:
CD86=3.2263.22, CCR7=0.0060.00, p,0.05, Mann-Whitney
U test) (figure 5 & 6). However, at 1:5 cell ratios HLA-DR
expression was not significantly different in HLA-C1 DCs
compared with HLA-C2 DCs (159.97664.82 vs 94.42639.97,
p=NS). In general, CD86 and HLA-DR expression by DCs were
greater at cell ratios of 1:1 than 1:5. In co-culture, CCR7
expression occurred mainly on HLA-C1 DCs expressing alleles
(figure 5 & 6). CCR7 expression was more marked at NK-DC co-
culture cell ratios of 1:1 (10.3% versus 1.86%) (figure 6).
HLA-C2 expression by DC is associated with an anti-
inflammatory cytokine milieu in NK-DC co-culture
Supernatants were collected from NK-DC co-culture and tested
for cytokine synthesis using 25 cytokine multiplex bead immuno-
assay. From the cytokines analysed, 11 could be detected (as shown
on figures 7 and 8). Differential cytokine synthesis was compared
between HLA-C1 DC and HLA-C2 DC in co-culture in the
presence of 1 ng/ml IL-15. Data presented in figure 7 and 8 are
means 6 SEM for 4 independent experiments in each arm (HLA-
C1 versus HLA-C2) and takes into account background cytokine
production when DC/NK cells were in isolation. In NK-DC co-
culture at cell ratios of 1:1 (figure 7), significantly more TNF-a and
IL-12 were detected in supernatants from HLA-C1 DC (TNF-a:
123.5165.1 pg/ml; IL-12: 895.916302.73 pg/ml) compared to
HLA-C2 DC (TNF-a: 10.4263.02 pg/ml; IL-12: 354.716
64.23 pg/ml, p,0.05). In contrast, significantly more IP-10, IL-
6 and IL-1RA were detected in supernatants from HLA-C2 DC
(IP-10: 49.43615.22 pg/ml; IL-6: 1046.166191.54 pg/ml; IL-
1RA: 1175.036142.25 pg/ml) than HLA-C1 DC (IP-10: 10.926
1.34 pg/ml; IL-6: 126.25666.48 pg/ml; IL-1RA: 752.116
58.94 pg/ml, p,0.05). Other cytokines including RANTES,
Table 5. Causes of graft loss categorized by the absence or presence of HLA-C2.
Cause of graft loss
Absence of HLA-C2
(n=303)
Presence of HLA-C2
(n=457) P value
Chronic allograft injury 60 (20%) 64(14%) 0.03
Vascular thrombosis 16 (5.3%) 8 (1.7%) 0.01
Acute rejection 2 (0.7%) 5 (1.1%) NS
Recurrent of primary renal disease 2 (0.7%) 4 (1.1%) NS
Infection of allograft 1 (0.3%) 1 (0.3%) NS
Figures reported are absolute number of events and figures in brackets represent percentages calculated for events per HLA-C genotype. Statistical analysis was
performed by Kendall’s tau-b test. NS represents not significant.
doi:10.1371/journal.pone.0023631.t005
Figure 4. Immunohistochemistry slide demonstrating donor
derived CD56 positive cells (anti-CD56 antibody staining
brown in colour: arrow as indicator) in pre-transplant kidney
biopsy tissue. In brief, the method for development of this slide
included dewaxing and antigen retrieval obtained by W-cap system
(Bio-Optica) and staining with mouse monoclonal anti-CD56 antibody
(IgG2b Novocastra) used at a dilution of 1:50 and visualised with the
EnVision detection system (DAKO). This image is representative of the
observation made for biopsies taken from five different kidney
transplants studied. Cell counts (degree of infiltration) were performed
using light microscopy and counting 10 randomly selected high power
fields at a magnification of 4006 (area=0.17 mm
2). Mean (6SEM) of
362 CD56 positive cells were identified per high power field.
doi:10.1371/journal.pone.0023631.g004
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comparable quantities between groups. In NK-DC co-culture at
cell ratios of 1:5 (figure 8), significantly more IL-12 was detected in
supernatants from HLA-C1 DC (IL-12: 5825.28654.34 pg/ml)
compared with HLA-C2 DC (IL-12: 533.996129.51 pg/ml,
p,0.05). In contrast, significantly more IL-6 was detected in
supernatants from HLA-C2 DC (IL-6: 3564.486750.53 pg/ml)
than HLA-C1 DC (IL-6: 424.076179.14 pg/ml, p,0.05). Other
cytokines including RANTES, MIG, interferon-c, interferon-a,
TNF-a, IL-10, IL-1RA and IL-1b were detected at comparable
quantities between the groups. TNF-a and IL-12 are potent
inducers of DC maturation whereas IL-6 and IL-1RA have been
shown to inhibit DC maturation. This differential cytokine profile
is consistent with the observation that, in co-culture with NK cells,
HLA-C1 DC expressed more CD86, HLA-DR and CCR7 than
HLA-C2 DC. Diminished TNF-a synthesis during co-culture at
cell ratios of 1:5 (figure 8) may explain the lower expression of
CD86, HLA-DR and CCR7 when compared to 1:1 cell ratios
(figure 7).
Discussion
In contrast to liver transplantation, recipient expression of a
HLA-C2 allele had a strong impact on clinical outcomes following
kidney transplantation. We found that kidney transplant recipients
with a HLA-C2 allele had a 21.9% death non-censored and 19.9%
death censored better graft survival at 10 years when compared to
recipients without the allele. Recipients with either a HLA-C2
homozygous or heterozygous allele had similar graft survival
benefits, suggesting that gene dose does not have a strong effect in
this setting. The relative risk of graft loss for kidney transplant
recipients without a HLA-C2 allele was 1.5 times that of recipients
Figure 5. Comparisons are made for DMFI of CD86, HLA-DR and CCR7 expression between DCs with either HLA-C1 or HLA-C2
homozygous allele. Data shown are DMFI of CD86, HLA-DR and CCR7 expressed by DC in NK-DC co-culture in the presence of 1 ng/ml IL-15 at cell
ratios of either 1:1 or 1:5. DMFI are calculated as the difference of MFI for DC in co-culture versus DC in isolation i.e. spontaneous expression. In NK-DC
co-culture, in the presence of IL-15, DC with HLA-C1 homozygous allele express more co-stimulation molecules, and MHC class II molecules than DC
with HLA-C2 homozygous alleles. Furthermore expression of trafficking chemokine CCR7 is virtually exclusive to HLA-C1 homozygotes indicating
their predominant role in T-cell immune priming in secondary lymphoid tissues. Data shown for 4 independent experiments performed in each group
and * indicates statistical significance with p,0.05 by Mann Whitney U test.
doi:10.1371/journal.pone.0023631.g005
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recipient was further confirmed by multivariable analysis. Re-
transplants were included because analysing re-transplant cases
alone demonstrated similar survival benefits; this observation is
fundamentally important as it further emphasizes the reliability of
this data, through a recipient derived effect that is maintained even
in re-transplantation. 10-year patient survival was also superior in
the HLA-C2 positive recipients. However this effect was not
significant in the multivariable analysis; this indicates any
associations of recipient HLA-C2 allele with patient survival
independent of graft loss will be weak. People with kidney
transplant failure are treated with dialysis and therefore rarely die
from graft failure. Causes of graft loss were analysed in the context
of the absence or presence of HLA-C2; this analysis demonstrated
that the absence of HLA-C2 was associated with more chronic
allograft injury and vascular thrombosis.
Whilst HLA mismatching is known to influence graft survival
our study was not designed to detect these as the number of cases
per HLA mismatch were small. Other observations made on the
multivariable analysis including a lack of a consistent benefit seen
with HLA matching, variable effects seen for increasing recipient
age with graft and patient survival, and the beneficial effect on
patient survival in the tacrolimus group must be interpreted with
caution as this study was not designed to investigate these
parameters. In particular patients from our clinical centre who
were started on tacrolimus were generally younger patients which
may have had a direct impact on survival outcomes.
We also tested the impact of the ‘missing self’ model on kidney
transplant outcomes as previously performed by Tran and
colleagues [18]. Consistent with their observations, we found no
correlation between KIR ligand mismatch and graft survival.
HLA-C ligand matching also did not influence the rate of acute
rejection.
Kunert and colleagues [16] studied the relationship between the
incidence of acute rejection after kidney transplantation and
various KIR genotypes for a cohort of 224 patients. They found a
reduced incidence of acute rejection when the donor was HLA-C2
homozygous. In contrast with their work, we found no significant
association between a donor HLA-C2 homozygous genotype and
acute rejection. More broadly, we tested both donor and recipient
Figure 6. Flow cytometer data illustrating the impact of IL-15 (1 ng/ml) treated NK-DC co-culture on the expression of DC
maturation (HLA-DR FITC) and chemokine (CCR7 PE) markers, comparing responses for DCs with either HLA-C1 (figures 6b, d, f) or
HLA-C2 (figures 6c, e, g) homozygous alleles. (a) shows DC stained with isotype control for HLA-DR & CCR7, (b) & (c) shows background DC
staining where DCs are in isolation in the presence of IL-15, (d) & (e) shows HLA-DR & CCR7 expression by DC in NK-DC co-culture at ratios of 1:1 in
the presence of IL-15, (f) & (g) shows DC markers in NK-DC co-culture at ratios 1:5 in the presence of IL-15. This data clearly demonstrates that in NK-
DC co-culture at ratios of 1:1 in the presence of IL-15, HLA-C1 homozygous DCs undergo significantly greater maturation than HLA-C2 homozygous
DCs and attain CCR7 chemokine expression required for trafficking to secondary lymphoid tissues. Results are representative of 4 experiments with
5,000 DC gated events captured.
doi:10.1371/journal.pone.0023631.g006
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PLoS ONE | www.plosone.org 9 August 2011 | Volume 6 | Issue 8 | e23631Figure 7. Supernatants were collected from NK-DC co-culture experiments at cell ratios of 1:1 treated with IL-15 and tested for
cytokine synthesis using 25 cytokine multiplex bead immunoassay. Data shown are for all the cytokines that were expressed in culture
supernatants. Of these, comparisons were made between cytokine synthesis for DCs with either HLA-C1 homozygous allele or DCs with HLA-C2
homozygous alleles. Data shown excludes background synthesis by cells in isolation. These data indicates that DC with HLA-C1 alleles express
significantly greater pro-inflammatory cytokines in NK-DC co-culture favouring immune maturation whereas DC with HLA-C2 alleles predominantly
express anti-inflammatory cytokines that are inhibiting to DC maturation. Means 6 SEM for 4 independent experiments in each group are shown and
* indicates statistical significance with p,0.05 by Mann-Whitney U test.
doi:10.1371/journal.pone.0023631.g007
Figure 8. Supernatants were collected from NK-DC co-culture experiments at cell ratios of 1:5 treated with IL-15 and tested for
cytokine synthesis using 25 cytokine multiplex bead immunoassay. Data shown are for all the cytokines that were expressed in culture
supernatants. Of these, comparisons were made between cytokine synthesis for DCs with either HLA-C1 homozygous allele or DCs with HLA-C2
homozygous alleles. Data shown excludes background synthesis by cells in isolation. These data indicates that DC with HLA-C1 alleles express
significantly greater pro-inflammatory cytokines in NK-DC co-culture favouring immune maturation whereas DC with HLA-C2 alleles predominantly
express anti-inflammatory cytokines that are inhibiting to DC maturation. Means 6 SEM for 4 independent experiments in each group are shown and
* indicates statistical significance with p,0.05 by Mann-Whitney U test.
doi:10.1371/journal.pone.0023631.g008
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or KIR haplotypes and acute rejection in 657 kidney transplant
patients. The explanation for the conflicting findings may relate to
their small study size (HLA-C2 homozygous, n=31, p=0.052),
and reflect a type I statistical error.
The organ specific directional benefit of possession of HLA-C2
allele (recipients with a HLA-C2 allele in kidney transplants and
donors with HLA-C2 allele in liver transplants [15]) is of great
interest. These observations are consistent with other data that
liver and kidney transplants develop immunological responses
through different mechanisms [36,37].
In experimental models of transplantation, liver allografts have
been shown to be immune privileged, with evidence for tolerance
against T cells [38–40]. The mechanisms described include
induction of CD8
+ T-cell apoptosis [38], inhibition of CD4
+ T-
cell mediated Th1 differentiation [39] and production of the anti-
inflammatory cytokine IL-10 [40]. In clinical transplantation, liver
allografts are transplanted without HLA matching and prior
knowledge of anti-donor HLA antibodies. HLA matching is not
associated with improvement in long-term graft survival after liver
transplantation [41]. Therefore current evidence indicates that
chronic rejection may be attributable to recipient NK cells
targeting donor tissue [15,37,42–45]. Based on our hypothesis, an
absence of HLA-C2 allele on the allograft would lead to NK cell
activation with consequent liver transplant damage [15]. Con-
versely kidney transplants are highly susceptible to all components
of the adaptive immune system. CAI occurs through adaptive
immune processes involving T cells, B cells and anti-HLA
antibodies [46]. Therefore the associations between the recipient
HLA-C2 allele and survival benefit may be linked to the
maturation of adaptive immunity facilitated by interactions
between donor-derived NK cells and recipient antigen presenting
cells (stimuli for indirect allorecognition) in the early post-
transplant period. Indeed, there is good evidence linking indirect
allorecognition to poor long-term graft function in kidney
transplantation [47–49].
The increased understanding of NK cell biology in the past
decade has been based on studies that have assessed interactions
between NK cells and DC. DC are professional antigen presenting
cells with very potent T-cell priming ability [50]. Recently,
activated NK cells were shown to interact with DC to efficiently
induce their maturation [51–53]. Subsequently, Brilot and
colleagues [27] showed polarisation of KIR and KIR ligands to
the site of cell-cell contact in NK-DC co-culture indicating that
this interaction is involved in NK-DC cross talk. Vitale and
colleagues [26] showed that the predominant activation signal in
NK mediated DC maturation occurs with engagement of the
natural cytotoxic receptor NKp30. This signal was modulated by
blocking antibodies against a HLA specific inhibitory receptor
(A6/136 IgM), indicating the involvement of KIRs and KIR
ligands. Therefore, at the NK-DC immune synapse, HLA-C2
expression by DC may inhibit DC maturation following
engagement with KIR 2DL1, with a consequent impact on
priming of the adaptive immune system.
Potent NK-DC interactions require a favourable cytokine
milieu [51], and one important cytokine in this setting is IL-15
[27]. Kidney tissue constitutively expresses IL-15 [31,33], with up-
regulated expression in the early stages post-transplantation
[32,54]. Unlike IL-2, IL-15 synthesis is not abrogated by anti-
CD25 monoclonal antibody treatment [55]. Furthermore, IL-15
induced activation of NK cells is not inhibited by conventional
induction immunosuppression with methylprednisolone [56] and
encourages potent NK-DC interactions.
We developed an allogeneic NK-DC co-culture model which is
relevant to the setting of kidney transplantation. In support of the
validity of this model, immunohistochemical studies performed on
pre-transplant kidney tissue confirms that donor derived NK cells
are present in the allograft at the time of the transplant. Following
transplantation, with up-regulation of constitutively expressed IL-
15 [31,33,54] donor NK cells interact with immature DC. We
demonstrated that on in-vitro allogeneic NK-DC co-culture,
significant DC maturation occurred following treatment with
1 ng/ml of IL-15 and this process was cell contact dependent. DC
maturation occurred at NK-DC cell ratios of either 1:1 or 1:5, but
not when NK cells were in excess of DC at a ratio of, 5:1. NK-DC
cell ratios of 1:1 were maximally inductive for DC maturation.
This observation is very relevant to the clinical setting, as donor
derived cells may be at lower numbers than recipient cells
following allograft reperfusion.
We made the novel observation that in NK-DC co-culture, the
HLA-C allele expressed by DC influenced the degree of DC
maturation. In co-culture, HLA-C1 DC (without HLA-C2 allele)
underwent more maturation with greater expression of CD86 (a
co-stimulation molecule) and HLA-DR (a MHC class II
molecules) when compared to HLA-C2 DC. Furthermore,
CCR7, a chemokine receptor required for cell trafficking to
secondary lymphoid tissue [57] was exclusively expressed by HLA-
C1 DC. CCR7 expression has been shown to enhance DC
migratory speed [58,59] and survival [60]. Therefore HLA-C1
DC (without HLA-C2 allele), matured in-situ in the days following
kidney transplantation, acquire the capacity to migrate to
secondary lymphoid tissue, where they will present antigen to
promote the activation and proliferation of T cells specific for graft
antigen [61]. Conversely, DC with HLA-C2 allele express low
level CD86 and HLA-DR with no CCR7 expression. This may
make them inefficient at T-cell priming but may provide them
with tolerogenic potential [62,63].
Supernatants from NK-DC co-culture were also assessed for the
presence of cytokines. At cell ratios of 1:1 in presence of 1 ng/ml
of IL-15, TNF-a and IL-12 were detected at significantly higher
concentrations for HLA-C1 DC than HLA-C2 DC. Conversely,
IP-10, IL-6 and IL-1 receptor antagonist (IL-1RA) were detected
at higher concentrations with HLA-C2 DC than with HLA-C1
DC. These cytokine profiles are consistent with the observation of
enhanced cell surface maturation markers for HLA-C1 DC and a
failure of efficient maturation for HLA-C2 DC in co-culture.
TNF-a and IL-12 are pro-inflammatory cytokines involved in DC
maturation [21–23]. IL-12 synthesised by DC in NK-DC co-
culture has been shown to augment the activation status of NK
cells [64]. This in-turn may favour further IFN-c, TNF-a, and
GM-CSF, encouraging DC maturation [65]. The cytokine profiles
noted for HLA-C2 DC are anti-inflammatory; the increased IP-10
synthesis may reflect the prolonged contact of ineffective DCs with
NK cells. This may be relevant in the process of DC editing.
Furthermore, IL-6 inhibits NF-kB binding activity and CCR7
expression [66], therefore inhibiting DC maturation. IL-1 is a
powerful pro-inflammatory cytokine profoundly inhibited by IL-1
receptor antagonist (IL-1RA). The role of IL-1RA in human
diseases is well described [67]. Up-regulation of IL-1RA may
therefore impede DC maturation in HLA-C2 DCs.
Based on these observations, recipients without HLA-C2 alleles
are at greater risk of accelerated DC maturation compared with
recipients with HLA-C2 alleles. As a consequence recipients
without a HLA-C2 allele are subjected to a greater immunological
load through T-cells primed by indirect allorecognition.
In conclusion, early events in kidney transplantation involving
donor NK cells and recipient DC interactions via KIR and HLA-
KIR/HLA-C Influences Kidney Transplant Outcomes
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priming; this is determined by the recipient HLA-C genotype.
Graft survival outcomes are related to these processes, which
therefore represent a prime target for therapeutic intervention to
prolong allograft survival. Furthermore, recipients with the HLA-
C2 allele may be at lower immunological risk and may therefore
benefit from the minimisation of immunosuppression.
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